Abstract
Associations have been reported between an MDR1 variant and responses to nonnucleoside reverse-transcriptase inhibitors. We explored associations between MDR1, CYP2B6, and CYP3A polymorphisms and nevirapine hepatotoxicity. Among participants in a randomized study in South Africa (FTC-302), MDR1 3435C-->T was significantly associated with decreased risk of hepatotoxicity (risk ratio, 0.30; P=.016).
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / metabolism
-
Anti-HIV Agents / therapeutic use
-
Aryl Hydrocarbon Hydroxylases / genetics
-
Case-Control Studies
-
Chemical and Drug Induced Liver Injury*
-
Cytochrome P-450 CYP2B6
-
Cytochrome P-450 CYP3A
-
Cytochrome P-450 Enzyme System / genetics*
-
Female
-
Gene Frequency
-
Genes, MDR*
-
Genotype
-
HIV Infections / drug therapy
-
HIV-1
-
Humans
-
Liver / drug effects
-
Liver Diseases / genetics
-
Liver Diseases / virology
-
Male
-
Nevirapine / adverse effects*
-
Nevirapine / metabolism
-
Nevirapine / therapeutic use
-
Oxidoreductases, N-Demethylating / genetics
-
Polymorphism, Genetic
-
Randomized Controlled Trials as Topic
-
Reverse Transcriptase Inhibitors / adverse effects*
-
Reverse Transcriptase Inhibitors / metabolism
-
Reverse Transcriptase Inhibitors / therapeutic use
-
South Africa
Substances
-
Anti-HIV Agents
-
Reverse Transcriptase Inhibitors
-
Cytochrome P-450 Enzyme System
-
Nevirapine
-
Aryl Hydrocarbon Hydroxylases
-
CYP2B6 protein, human
-
Cytochrome P-450 CYP2B6
-
Cytochrome P-450 CYP3A
-
CYP3A4 protein, human
-
Oxidoreductases, N-Demethylating